Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,272 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03345095 | A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma(MIRAGE) | completed | Phase 3 | 749 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Jul 1, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER |
| 1 |
| Jun 29, 2025 |
| clinicaltrials |
| NCT03745859 | Evaluation of a New Open Source Virtual Bronchoscope Navigation System | terminated | — | 4 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04111588 | Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases | recruiting | — | 160 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT02667587 | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)(CheckMate548) | completed | Phase 3 | 716 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2025 | clinicaltrials |
| NCT02848001 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | terminated | Phase 1 | 101 | CelgeneINDUSTRY | 6 | Jun 12, 2025 | clinicaltrials |
| NCT06709248 | Feasibility of a Life Coping Program: A Study Protocol(LifeCOPE) | completed | N/A | 54 | Haukeland University HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03831776 | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis(BosuPeg) | completed | Phase 2 | 212 | St. Olavs HospitalOTHER | 4 | Jun 8, 2025 | clinicaltrials |
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT02041845 | Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer(THORA) | active not recruiting | N/A | 177 | Norwegian University of Science and TechnologyOTHER | 3 | Jun 6, 2025 | clinicaltrials |
| NCT02562131 | PET-MR-PSA Prostate Cancer Recidive Study(PET-MR-PSA) | active not recruiting | — | 80 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT03072238 | Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer(IPATential150) | completed | Phase 3 | 1,101 | Hoffmann-La RocheINDUSTRY | 26 | Jun 6, 2025 | clinicaltrials |
| NCT01550237 | Curative Image Guided Radiotherapy for Prostate Cancer(RIC) | active not recruiting | N/A | 260 | St. Olavs HospitalOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT02546232 | Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting | active not recruiting | Phase 2 | 196 | Oslo University HospitalOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03317327 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors(REPORT) | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03011268 | Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?(BIOSTOP) | completed | N/A | 174 | Helse Møre og Romsdal HFOTHER_GOV | 1 | May 31, 2025 | clinicaltrials |
| NCT06398314 | Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors(PALLSOFT) | recruiting | N/A | 200 | Sykehuset TelemarkOTHER_GOV | 1 | May 23, 2025 | clinicaltrials |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | completed | Phase 3 | 945 | Bristol-Myers SquibbINDUSTRY | 22 | May 21, 2025 | clinicaltrials |
| NCT06435091 | REBECCA-3 Study, Research on Breast Cancer Induced Chronic Conditions Supported by Causal Analysis of Multi-source Data(REBECCA-3) | active not recruiting | — | 40 | Helse Stavanger HFOTHER_GOV | 1 | May 16, 2025 | clinicaltrials |
| NCT06914648 | The Dragon PLC Trial (DRAGON-PLC) | recruiting | N/A | 358 | Maastricht UniversityOTHER | 12 | May 15, 2025 | clinicaltrials |
| NCT01526369 | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer(TH V THL) | completed | Phase 3 | 75 | Cancer Trials IrelandNETWORK | 8 | May 9, 2025 | clinicaltrials |
| NCT04186585 | Recommended Dose Estimation of BP-C2 | recruiting | Phase 1 | 8 | MeddocOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06307938 | Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer(CoLiQ) | recruiting | — | 3,000 | Helse Nord-Trøndelag HFOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | active not recruiting | Phase 2 | 250 | Partner Therapeutics, Inc.INDUSTRY | 18 | Apr 29, 2025 | clinicaltrials |
| NCT03551626 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes(COMBI-APlus) | completed | Phase 3 | 552 | Novartis PharmaceuticalsINDUSTRY | 23 | Apr 29, 2025 | clinicaltrials |
| NCT06947382 | Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer(CLARITI) | completed | — | 1,066 | Immunovia, Inc.INDUSTRY | 4 | Apr 27, 2025 | clinicaltrials |
| NCT06944587 | A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer(NORPACT-3) | recruiting | — | 400 | Oslo University HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02388906 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma(CheckMate 238) | completed | Phase 3 | 906 | Bristol-Myers SquibbINDUSTRY | 25 | Apr 24, 2025 | clinicaltrials |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 376 | Bristol-Myers SquibbINDUSTRY | 17 | Apr 24, 2025 | clinicaltrials |
| NCT06935487 | European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection(PCaVISTA) | active not recruiting | N/A | 806 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 6 | Apr 20, 2025 | clinicaltrials |
| NCT00472459 | Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer | completed | Phase 3 | 82 | Galderma R&DINDUSTRY | 5 | Apr 18, 2025 | clinicaltrials |
| NCT06324409 | ImmigrantScreen Telephone Reminder Trial in Colorectal Cancer Screening | completed | N/A | 400 | Norwegian Institute of Public HealthOTHER_GOV | 1 | Apr 15, 2025 | clinicaltrials |
| NCT05609942 | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies(AZURE) | terminated | Phase 1 | 9 | Blueprint Medicines CorporationINDUSTRY | 7 | Apr 10, 2025 | clinicaltrials |
| NCT03903835 | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer(ProBio) | recruiting | Phase 3 | 750 | Karolinska InstitutetOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT02288247 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone(PRESIDE) | completed | Phase 3 | 688 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia(ENHANCE-3) | terminated | Phase 3 | 378 | Gilead SciencesINDUSTRY | 20 | Apr 4, 2025 | clinicaltrials |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | active not recruiting | Phase 2 | 120 | Raija SilvennoinenOTHER | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03668652 | Focal Prostate Ablation Versus Radical Prostatectomy(FARP) | completed | N/A | 213 | Oslo University HospitalOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT02249572 | Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.(V-REX) | completed | N/A | 100 | Haukeland University HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05834348 | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.(DELINOR) | completed | — | 5,279 | PfizerINDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06119789 | Precision Cancer Therapy in Rare Cancers(MATRIX-Rare) | recruiting | Phase 2 | 96 | Oslo University HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT02312960 | Radium-223 Dichloride Long-term Follow-up Program | completed | Phase 4 | 255 | BayerINDUSTRY | 22 | Mar 25, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT01937780 | Anal Cancer Radiotherapy Study(ANCARAD) | active not recruiting | — | 75 | Oslo University HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02939612 | Stress Management Intervention in Early Stage Cancer: Randomized Controlled Trial | active not recruiting | N/A | 200 | Oslo University HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04513639 | The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | recruiting | Phase 2 / Phase 3 | 176 | Oslo University HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04939844 | REST - Replacing Steroids in the Transplant Ineligble(REST) | completed | Phase 2 | 51 | Oslo University HospitalOTHER | 2 | Mar 20, 2025 | clinicaltrials |
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients(SABLe) | active not recruiting | Phase 2 | 50 | Ida Bruun KristensenOTHER | 3 | Mar 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials